Bengaluru-based biopharmaceutical company PlasmaGen Biosciences has raised ₹150 crore in a fresh funding round led by ViNS Bioproducts, with participation from high-net-worth individuals, family offices, pharmaceutical entrepreneurs, and existing investors. Following the infusion, the company’s valuation has climbed to over ₹1,500 crore, highlighting strong investor conviction in PlasmaGen’s niche business and long-term strategy.
The funding comes at a time when India’s healthcare ecosystem is placing renewed emphasis on domestic manufacturing of critical medicines, especially in areas that have long depended on imports. PlasmaGen’s focus on plasma-derived therapies positions it at the centre of this shift.
Credits: Business Standard
A Decade-Long Journey Backed by Global Capital
Founded in 2010 by Vinod Nahar, PlasmaGen Biosciences has steadily built a reputation in one of the most complex and regulated segments of biopharma. With the latest round, the company has now raised over ₹600 crore since inception.
Over the years, PlasmaGen has attracted marquee global investors including Fidelity’s FIL Capital Investments, Eight Roads Ventures, and F-Prime Capital. This consistent institutional backing has enabled the company to invest patiently in infrastructure, compliance, and specialised capabilities—critical ingredients in a capital-intensive sector where quick wins are rare.
The ability to repeatedly raise capital also signals confidence in PlasmaGen’s execution discipline and its long-term vision of building a sustainable plasma ecosystem in India.
Strategic Use of Fresh Capital
PlasmaGen plans to deploy the newly raised funds across three core priorities: international expansion, product portfolio growth, and strengthening manufacturing and leadership capabilities.
As the company prepares for global markets, it is investing in operational depth and regulatory readiness—essential for plasma-derived therapies that require strict quality controls and compliance across jurisdictions. Leadership expansion is also a key focus, reflecting the specialised expertise needed across production, quality assurance, and distribution.
These investments are expected to help PlasmaGen evolve from a largely India-focused player into a biopharma company with international ambitions.
Addressing India’s Plasma Medicine Shortfall
PlasmaGen operates in a segment that remains critically underserved in India. The company develops and commercialises plasma-derived therapies such as Immunoglobulin, Albumin, and clotting factors, which are essential for treating neurological disorders, blood-related conditions, immune deficiencies, and critical care patients.
Historically, India has relied heavily on imports for plasma-derived medicines, often leading to shortages and high costs. PlasmaGen aims to narrow this gap by building domestic capacity, improving availability, and ensuring a reliable supply of life-saving therapies.
In doing so, the company aligns closely with broader national priorities around healthcare self-reliance.
A Modern Manufacturing Hub Near Bengaluru
At the core of PlasmaGen’s operations is its plasma fractionation facility in Kolar, Karnataka, located near Bengaluru. The plant began commercial operations in 2024 and is among only five such facilities currently operating in India.
Designed to meet stringent global quality and safety standards, the Kolar facility represents a significant investment in local biopharma manufacturing. Since commercialisation, PlasmaGen reports strong revenue growth, driven by increasing demand from hospitals and healthcare providers.
Expanding Reach Across India’s Healthcare Network
India continues to be PlasmaGen’s primary market, even if international expansion is a major objective. Through a strong, cold-chain-enabled distribution network, the company is gradually increasing its presence among hospitals and doctors.
For plasma-derived treatments, temperature-controlled logistics are essential, and PlasmaGen’s emphasis on distribution infrastructure is crucial to guaranteeing the efficacy and safety of its products. The corporation wants to expand patient access across regions by strengthening its ties with healthcare providers.
/entrackr/media/media_files/2025/12/22/plasmagen-biosciences-2025-12-22-16-49-33.png)
Credits: Entrackr
Laying the Groundwork for Global Markets
PlasmaGen is in the process of obtaining the required regulatory permits for international sales and has already found distribution partners in a few foreign regions. These initiatives signify the company’s next stage of expansion as it seeks to enhance its domestic footprint through exports.
PlasmaGen is establishing a focused identity in a specialized industry where scale, quality, and long-term commitment are more important than speed by positioning itself as the first pure-play plasma biopharma firm in India. The company seems ready to embark on its next phase of expansion, with its manufacturing base located in Karnataka and its worldwide aspirations taking shape.
